For all the newcomers here, please have a look at the interview with the Cynata's Executive Chairman from February 2016 (almost exactly 1 year ago):
https://www.streetwisereports.com/p...s-money-stewart-washer-of-cynata-therapeutics
Here are a few highlights:
"For a dozen years, MSCs have been featured in a wide range of medical trials, often demonstrating success for treating lethal diseases. Clinical trials of MSCs are showing good results for healing damage from heart disease and strokes. And MSCs are demonstrating healing properties for serious autoimmune diseases, such as Crohn's disease."
"The problem with available MSC treatments is that the technology can only make a few hundred doses at once. State-of-the-art techniques cannot make multiple doses from a single donor, because donor-dependent stem cells quickly lose potency. That forces MSC firms to look for new donors and start up the manufacturing process over and over again."
"Right now, MSC-based treatments are boutique—very expensive because of the need to continually locate streams of new donors. Our non-donor-dependent method will transform stem cell medicine into an affordable and potent off-the-shelf product. It will not be sold over the counter, but it will be available at the right price as prescribed by a doctor. Our major breakthrough is being able to create uniform batches of MSCs at a reasonable price."
"Hundreds of millions of people are affected by strokes, heart disease, and Crohn's disease. They will demand this medicine, and we can provide it at good value."
"The trial is to treat GvHD with our patented MSCs. We are taking 16 patients into a Phase 1/2 study. We will dose them with our mesenchymal stem cells at a rate of 1 to 2 million cells per kilogram, or a few hundred million cells for each individual. We are looking at safety issues, but MSCs are already proven to be safe.
At 28 days post-injection, if the patients are sitting up in bed or walking around, the product will have worked."
"No one has cracked the unlimited expansion of MSCs other than us. We own the space at the moment, alongside the University of Wisconsin. Someone will eventually compete with us, but
we are many years ahead of the pack."
"Inventive companies are constantly finding new uses for mesenchymal stem cells, and we control the most revolutionary manufacturing technology for the foreseeable future. The endgame is to get that technology into the hands of big pharma and big biotech. When Johnson & Johnson moves into stem cells, its executives do not want to see a line of bone marrow donors cued outside the MSC factory. They want the technology encased inside stainless steel tanks: Turn the handle and get another batch of MSC doses ready to use. That is exactly what we can give deliver."
"We are developing a lung fibrosis product with Dr. Geoff Laurent out of the University of Western Australia. A world leader in lung fibrosis research, Dr. Laurent is conducting preclinical studies using our cells. We partnered with the University of Sydney, whose Dr. James Chong is a leading heart surgeon and researcher. Our partner at Harvard University is Dr. Khalid Shah, a leading researcher in brain tumors. Dr. Shah is using mesenchymal stem cells to treat glioblastoma.
We will launch a new pipeline after positive results of the GvHD trial emerge."
Note: 28 days post-injection (see above)??
(20min delay)
